Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

Timothy S. Fenske, Kwang W. Ahn, Tara M. Graff, Alyssa DiGilio, Qaiser Bashir, Rammurti T. Kamble, Ernesto Ayala, Ulrike Bacher, Jonathan E. Brammer, Mitchell Cairo, Andy Chen, Yi Bin Chen, Saurabh Chhabra, Anita D'Souza, Umar Farooq, Cesar Freytes, Siddhartha Ganguly, Mark Hertzberg, David Inwards, Samantha Jaglowski & 10 others Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Sunita Nathan, Attaphol Pawarode, Miguel Angel Perales, Nishitha Reddy, Sachiko Seo, Anna Sureda, Sonali M. Smith, Mehdi Hamadani

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four groups: low-risk (0 points), intermediate-risk (2-5 points), high-risk (6-9 points) or very high-risk (11 points), predicting 3-year PFS of 40, 32, 11 and 6%, respectively, with 3-year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT after a failed prior autoHCT.

Original languageEnglish (US)
Pages (from-to)235-248
Number of pages14
JournalBritish Journal of Haematology
Volume174
Issue number2
DOIs
StatePublished - Jul 1 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Autologous Transplantation
Cell Transplantation
Homologous Transplantation
Karnofsky Performance Status
Disease-Free Survival
Survival
Bone Marrow
Transplants
Multivariate Analysis
Research
Recurrence
Patient Selection
Disease Progression
Databases
Mortality

Keywords

  • Allogeneic transplantation
  • DLBCL
  • Prior autologous transplan
  • Prognostic score

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology

Cite this

Fenske, T. S., Ahn, K. W., Graff, T. M., DiGilio, A., Bashir, Q., Kamble, R. T., ... Hamadani, M. (2016). Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. British Journal of Haematology, 174(2), 235-248. https://doi.org/10.1111/bjh.14046

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. / Fenske, Timothy S.; Ahn, Kwang W.; Graff, Tara M.; DiGilio, Alyssa; Bashir, Qaiser; Kamble, Rammurti T.; Ayala, Ernesto; Bacher, Ulrike; Brammer, Jonathan E.; Cairo, Mitchell; Chen, Andy; Chen, Yi Bin; Chhabra, Saurabh; D'Souza, Anita; Farooq, Umar; Freytes, Cesar; Ganguly, Siddhartha; Hertzberg, Mark; Inwards, David; Jaglowski, Samantha; Kharfan-Dabaja, Mohamed A.; Lazarus, Hillard M.; Nathan, Sunita; Pawarode, Attaphol; Perales, Miguel Angel; Reddy, Nishitha; Seo, Sachiko; Sureda, Anna; Smith, Sonali M.; Hamadani, Mehdi.

In: British Journal of Haematology, Vol. 174, No. 2, 01.07.2016, p. 235-248.

Research output: Contribution to journalArticle

Fenske, TS, Ahn, KW, Graff, TM, DiGilio, A, Bashir, Q, Kamble, RT, Ayala, E, Bacher, U, Brammer, JE, Cairo, M, Chen, A, Chen, YB, Chhabra, S, D'Souza, A, Farooq, U, Freytes, C, Ganguly, S, Hertzberg, M, Inwards, D, Jaglowski, S, Kharfan-Dabaja, MA, Lazarus, HM, Nathan, S, Pawarode, A, Perales, MA, Reddy, N, Seo, S, Sureda, A, Smith, SM & Hamadani, M 2016, 'Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation', British Journal of Haematology, vol. 174, no. 2, pp. 235-248. https://doi.org/10.1111/bjh.14046
Fenske, Timothy S. ; Ahn, Kwang W. ; Graff, Tara M. ; DiGilio, Alyssa ; Bashir, Qaiser ; Kamble, Rammurti T. ; Ayala, Ernesto ; Bacher, Ulrike ; Brammer, Jonathan E. ; Cairo, Mitchell ; Chen, Andy ; Chen, Yi Bin ; Chhabra, Saurabh ; D'Souza, Anita ; Farooq, Umar ; Freytes, Cesar ; Ganguly, Siddhartha ; Hertzberg, Mark ; Inwards, David ; Jaglowski, Samantha ; Kharfan-Dabaja, Mohamed A. ; Lazarus, Hillard M. ; Nathan, Sunita ; Pawarode, Attaphol ; Perales, Miguel Angel ; Reddy, Nishitha ; Seo, Sachiko ; Sureda, Anna ; Smith, Sonali M. ; Hamadani, Mehdi. / Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. In: British Journal of Haematology. 2016 ; Vol. 174, No. 2. pp. 235-248.
@article{0995014955774ff0b362db729e95b406,
title = "Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation",
abstract = "For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37{\%} respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four groups: low-risk (0 points), intermediate-risk (2-5 points), high-risk (6-9 points) or very high-risk (11 points), predicting 3-year PFS of 40, 32, 11 and 6{\%}, respectively, with 3-year OS probabilities of 43, 39, 19 and 11{\%} respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT after a failed prior autoHCT.",
keywords = "Allogeneic transplantation, DLBCL, Prior autologous transplan, Prognostic score",
author = "Fenske, {Timothy S.} and Ahn, {Kwang W.} and Graff, {Tara M.} and Alyssa DiGilio and Qaiser Bashir and Kamble, {Rammurti T.} and Ernesto Ayala and Ulrike Bacher and Brammer, {Jonathan E.} and Mitchell Cairo and Andy Chen and Chen, {Yi Bin} and Saurabh Chhabra and Anita D'Souza and Umar Farooq and Cesar Freytes and Siddhartha Ganguly and Mark Hertzberg and David Inwards and Samantha Jaglowski and Kharfan-Dabaja, {Mohamed A.} and Lazarus, {Hillard M.} and Sunita Nathan and Attaphol Pawarode and Perales, {Miguel Angel} and Nishitha Reddy and Sachiko Seo and Anna Sureda and Smith, {Sonali M.} and Mehdi Hamadani",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/bjh.14046",
language = "English (US)",
volume = "174",
pages = "235--248",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

AU - Fenske, Timothy S.

AU - Ahn, Kwang W.

AU - Graff, Tara M.

AU - DiGilio, Alyssa

AU - Bashir, Qaiser

AU - Kamble, Rammurti T.

AU - Ayala, Ernesto

AU - Bacher, Ulrike

AU - Brammer, Jonathan E.

AU - Cairo, Mitchell

AU - Chen, Andy

AU - Chen, Yi Bin

AU - Chhabra, Saurabh

AU - D'Souza, Anita

AU - Farooq, Umar

AU - Freytes, Cesar

AU - Ganguly, Siddhartha

AU - Hertzberg, Mark

AU - Inwards, David

AU - Jaglowski, Samantha

AU - Kharfan-Dabaja, Mohamed A.

AU - Lazarus, Hillard M.

AU - Nathan, Sunita

AU - Pawarode, Attaphol

AU - Perales, Miguel Angel

AU - Reddy, Nishitha

AU - Seo, Sachiko

AU - Sureda, Anna

AU - Smith, Sonali M.

AU - Hamadani, Mehdi

PY - 2016/7/1

Y1 - 2016/7/1

N2 - For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four groups: low-risk (0 points), intermediate-risk (2-5 points), high-risk (6-9 points) or very high-risk (11 points), predicting 3-year PFS of 40, 32, 11 and 6%, respectively, with 3-year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT after a failed prior autoHCT.

AB - For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four groups: low-risk (0 points), intermediate-risk (2-5 points), high-risk (6-9 points) or very high-risk (11 points), predicting 3-year PFS of 40, 32, 11 and 6%, respectively, with 3-year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT after a failed prior autoHCT.

KW - Allogeneic transplantation

KW - DLBCL

KW - Prior autologous transplan

KW - Prognostic score

UR - http://www.scopus.com/inward/record.url?scp=84978080661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978080661&partnerID=8YFLogxK

U2 - 10.1111/bjh.14046

DO - 10.1111/bjh.14046

M3 - Article

VL - 174

SP - 235

EP - 248

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -